SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-252141
Filing Date
2022-09-27
Accepted
2022-09-27 16:05:33
Documents
13
Period of Report
2022-09-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d400712d8k.htm   iXBRL 8-K 26290
2 EX-3.1 d400712dex31.htm EX-3.1 188214
  Complete submission text file 0001193125-22-252141.txt   382992

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20220926.xsd EX-101.SCH 2861
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20220926_lab.xml EX-101.LAB 18741
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20220926_pre.xml EX-101.PRE 11711
7 EXTRACTED XBRL INSTANCE DOCUMENT d400712d8k_htm.xml XML 3577
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 221271150
SIC: 2836 Biological Products, (No Diagnostic Substances)